COLLEGIUM PHARMACEUTICAL, INC
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $780.6M | $631.4M | $566.8M | $463.9M | $276.9M |
| Cost of revenue | $317.3M | $254.1M | $240.6M | $254.4M | $126.3M |
| Gross profit | $463.3M | $377.3M | $326.2M | $209.5M | $150.6M |
| Selling, general & administrative | $284.8M | $210.4M | $159.2M | $172.2M | $119.0M |
| Research and development | — | $0 | $0 | $4.0M | $9.5M |
| Operating expenses | $283.6M | $207.4M | $159.2M | $176.2M | $133.0M |
| Operating income | $179.6M | $169.9M | $167.0M | $33.3M | $17.6M |
| Interest expense | $82.3M | $74.0M | $83.3M | $63.2M | $21.0M |
| Pretax income | $92.6M | $98.6M | $75.7M | -$28.8M | -$3.4M |
| Income tax expense | $29.7M | $29.4M | $27.6M | -$3.8M | -$74.9M |
| Net income | $62.9M | $69.2M | $48.2M | -$25.0M | $71.5M |
| Balance Sheet | |||||
| Cash and equivalents | $231.3M | $70.6M | $238.9M | $173.7M | $186.4M |
| Current assets | $691.4M | $482.3M | $537.6M | $420.0M | $315.5M |
| Total assets | $1.7B | $1.7B | $1.1B | $1.2B | $692.1M |
| Current liabilities | $440.0M | $509.5M | $457.9M | $433.7M | $279.6M |
| Total liabilities | $1.4B | $1.4B | $947.9M | $979.3M | $489.1M |
| Stockholders' equity | $301.7M | $228.8M | $195.4M | $194.8M | $202.9M |
| Cash Flow Statement | |||||
| Cash from operations | $329.3M | $205.0M | $274.7M | $124.2M | $103.6M |
| Depreciation and amortization | $4.2M | $3.9M | $3.5M | $2.7M | $1.7M |
| Stock-based compensation | $41.9M | $32.4M | $27.1M | $22.9M | $24.3M |
| Capital expenditure | $1.7M | $1.7M | $461,000 | $1.6M | $1.9M |
| Free cash flow | $327.6M | $203.3M | $274.3M | $122.6M | $101.6M |
| Share repurchases | $25.1M | $60.0M | $75.0M | $14.1M | $47.9M |
Shares outstanding 32.4M · Free float 72.2%
Annual filing data through FY ended December 31, 2025; float as of July 12, 2026.